Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Altimmune (ALT) Leases (2019 - 2025)

Altimmune (ALT) has disclosed Leases for 6 consecutive years, with $1.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Leases rose 351.52% to $1.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.6 million, a 351.52% increase, with the full-year FY2024 number at $1.6 million, up 351.52% from a year prior.
  • Leases was $1.6 million for Q4 2024 at Altimmune, down from $1.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $1.7 million in Q2 2024 to a low of $300000.0 in Q1 2024.
  • A 5-year average of $815270.6 and a median of $725500.0 in 2022 define the central range for Leases.
  • Biggest YoY gain for Leases was 351.52% in 2024; the steepest drop was 44.55% in 2024.
  • Altimmune's Leases stood at $903825.0 in 2020, then fell by 11.71% to $798000.0 in 2021, then fell by 25.31% to $596000.0 in 2022, then plummeted by 39.09% to $363000.0 in 2023, then skyrocketed by 351.52% to $1.6 million in 2024.
  • Per Business Quant, the three most recent readings for ALT's Leases are $1.6 million (Q4 2024), $1.7 million (Q3 2024), and $1.7 million (Q2 2024).